The effect of evolocumab on myocardial infarct size
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0005323
- Lead Sponsor
- BUCHEON SEJONG HOSPITA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 166
1) 30-80 years of age
2) >30 minutes in duration of typical chest pain
3) =1 mm of ST-segment elevation on = 2 contiguous leads
4) Onset of ischemic symptoms <12 hours ago
5) agree with study enrollment
1) Prior myocardial infarction
2) Previous history of coronary artery bypass graft
3) Cardiogenic shock or cardiac arrest of more than 10 min
4) Acute left main coronary artery occlusion
5) Pregnancy or have a plan for pregnancy
6) Serum creatinine >2.5 mg/dL or hemodialysis is required
7) Expected survival < 1 year or poor compliance
8) Contraindication to cardiac MRI
9) previous administration of evolocumab within one month
10) body weight less than 40 kg
11) hypersensitivity or allergy to study drugs
12) active liver disease or high serum aminotransferase levels
13) genetic problems such as muscle disease, cyclosporin co-administration, galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method percent myocardial infarct size
- Secondary Outcome Measures
Name Time Method Incidence of microvascular obstruction;ST-segment resolution;Area under the curve of enzymatic infarct size;Myocardial blush grade;Corrected TIMI frame count;TIMI myocardial perfusion grade;CPK, Triglyceride, HDL-Cholesterol, LDL-Cholesterol, Hs-CRP, Lipoprotein(a) levels, P2Y12 reaction units levels